Not available
Quote | Cerecor Inc. (NASDAQ:CERC)
Last: | $2.93 |
---|---|
Change Percent: | -1.68% |
Open: | $2.98 |
Close: | $2.93 |
High: | $2.98 |
Low: | $2.9 |
Volume: | 266,862 |
Last Trade Date Time: | 08/25/2021 04:41:35 am |
News | Cerecor Inc. (NASDAQ:CERC)
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...
Message Board Posts | Cerecor Inc. (NASDAQ:CERC)
Subject | By | Source | When |
---|---|---|---|
New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/ | AliasUser1 | investorshub | 09/14/2021 10:00:46 PM |
$cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021- | frankkruemmel | investorshub | 05/11/2021 4:41:12 PM |
And up 25% this morning | JohnLocke101 | investorshub | 05/11/2021 1:43:22 PM |
Biggest negative operating margin ever seen -706.02%, book | make it happen | investorshub | 05/11/2021 1:28:10 PM |
https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets | frankkruemmel | investorshub | 05/11/2021 1:13:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront invest...